MICU1 and ovarian carcinoma: A recent study demonstrated that MICU1 was able to activate glycolysis and contributed to cisplatin-resistance in ovarian cancer, consequently promoting tumor growth and metastasis [18], suggesting its potential role in PTX-resistant ovary cancer.